Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02567903
Other study ID # NL49117.058.14
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2015
Est. completion date June 2019

Study information

Verified date February 2020
Source Groene Hart Ziekenhuis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Knee arthroscopy is the most commonly performed orthopaedic procedure worldwide, with, according to the American Society for Sports Medicine, over 4 million procedures performed each year. The risk of venous thrombosis following this procedure is considerable with rates of symptomatic events varying between 0.9% and 4.6%. It is currently unknown how this high risk comes about considering its short duration and minimal tissue damage caused by the procedure. A factor that may play a role is the use of a tourniquet. A large majority of orthopaedic surgeons prefer to operate within a 'dry field', which is obtained by the use of a tourniquet. Tourniquet applied surgery is not without risks. Although its use during orthopedic surgery is widely accepted and a standard procedure, tourniquet use can lead to loss of muscle functional strength and contractile speed, vessel wall damage and nerve injury, next to the possibly increased risk of venous thrombosis. In the proposed study the investigators will investigate the effect of a tourniquet on local and systemic markers of hypoxia, inflammation, involvement of endothelium, and coagulation activation. A finding of more prominent activation of the coagulation system with tourniquet use than with non-use will create an important opportunity to prevent thromboembolic events in these patients, as it has been shown that knee arthroscopy can be performed adequately without the use of a tourniquet. Furthermore, it will increase the understanding of the pathophysiology of thrombosis.


Description:

Background

Knee arthroscopy is the most commonly performed orthopaedic procedure worldwide, with, according to the American Society for Sports Medicine, over 4 million procedures performed each year. The risk of venous thrombosis following this procedure is considerable with rates of symptomatic events varying between 0.9% and 4.6%.

It is currently unknown how this high risk comes about considering its short duration and minimal tissue damage caused by the procedure. A factor that may play a role is the use of a tourniquet. A large majority of orthopaedic surgeons prefer to operate within a 'dry field', which is obtained by the use of a tourniquet. In the proposed study the investigators will investigate the effect of a tourniquet on local and systemic markers of hypoxia, inflammation, involvement of endothelium, and coagulation activation.

Objective

To investigate the effect of tourniquet application on the coagulation system in patients undergoing a knee arthroscopy. A finding of more prominent activation of the coagulation system with tourniquet use than with non-use will create an important opportunity to prevent thromboembolic events in these patients, as it has been shown that knee arthroscopy can be performed adequately without the use of a tourniquet. Furthermore, it will increase the understanding of the pathophysiology of thrombosis.

Study Design

In a randomized, controlled clinical study the investigators will compare local and systemic coagulation and inflammation markers before and after knee arthroscopy between two groups: 25 patients will be randomized to arthroscopy with tourniquet (Group I) and 25 patients to arthroscopy without tourniquet (Group II).

Inclusion and exclusion criteria

The patients will be recruited from one hospital in Gouda over a 6 months inclusion period. All patients over 18 years, scheduled for a meniscectomy, diagnostic arthroscopy or removal of corpora libera will be eligible for inclusion. Patients will be excluded when they suffer from any kind of coagulation disorder, use of hormonal anticonception, in case of pregnancy or puerperium, when they have a history of venous thrombosis, had major surgery or cast-immobilisation of the lower extremity in the past two months, have a neoplasm or inflammatory disease, have a BMI>30, or when they use anticoagulant therapy. Patients will generally receive spinal anaesthesia. Patients who are nevertheless exposed to any other type of anaesthesia will be excluded as well, to keep the effect of anaesthesia equal for all participants.

Intervention

Patients will be randomized to knee arthroscopy without tourniquet use and to knee arthroscopy with tourniquet use. In patients randomized to arthroscopy with tourniquet use, exsanguination in the leg in which the knee arthroscopy will be performed will be accomplished by raising the leg vertically for one minute. The tourniquet will be inflated to 100-150 mmHg above systolic blood pressure.

Data on duration of surgery and duration of tourniquet use will be collected. Blood collected from the cubital vein and the great saphenous vein during arthroscopy of the knee will be analyzed on outcome parameters that reflect a hypoxic state, an inflammatory reaction, involvement of the endothelium, a procoagulant state and thrombin formation.

Main study endpoints (primary)

Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery will be analyzed.

Different patterns will be analyzed to explore the effect of tourniquet application on the coagulation system by possible biological mechanism. A change (increase or decrease) of markers within one pattern, compared to baseline measurements (before surgery), is considered as a relevant shift of that pattern, thereby suggesting the involvement of that specific pathway.

Outcome parameters that reflect a hypoxic state:

- pH

- pO2

- pCO2

- Lactate

Outcome parameters that reflect an inflammatory reaction:

- White Blood Cell Count (WBCC)

- E-selectin

- Neutrophil Extracellular traps (NETs)

Outcome parameters that reflect involvement of the endothelium:

- Von Willebrand Factor (vWF)

- Thrombomodulin

- E-selectin

Outcome parameters that reflect a procoagulant state and thrombin formation:

- Prothrombin fragments 1+2

- D-dimer

- Plasmin Activator Inhibitor 1 (PAI 1)

- Tissue plasminogen activator (tPA)

- Factor VIII

- Thrombin and Antithrombin complexes (TAT)

- Plasmin and antiplasmin complexes (PAP)

Secondary study paramaters

• Visibility during arthroscopy and technical difficulty score.

Time Schedule

Month 1-3: Completion of study protocol, procedure for approval by METC. Set up of database and randomisation procedure. Instruction of participating clinicians and surgery/anaesthesia staff.

Month 4-6: Inclusion of patients, data collection. Month 7-8: Laboratory tests. Month 9-12: Data analysis, writing and submission of manuscript.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date June 2019
Est. primary completion date June 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria

- Meniscectomy

- Diagnostic arthroscopy

- Removal of corpora libera

Exclusion Criteria

- Any kind of coagulation disorder

- pregnant or within 3 months of childbirth

- Use of hormonal anticonception

- A history of venous thrombosis

- Had major surgery in the past two months

- A history of cast-immobilization of the lower extremity the past two months

- A neoplasm or inflammatory disease

- A BMI>30

- using anticoagulant therapy

- Any other anaesthesia technique than spinal anaesthesia

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Thigh Tourniquet
Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
Procedure:
Knee arthroscopy
Knee arthroscopy

Locations

Country Name City State
Netherlands Groene Hart Ziekenhuis Gouda Zuid Holland

Sponsors (2)

Lead Sponsor Collaborator
Groene Hart Ziekenhuis Leiden University Medical Center

Country where clinical trial is conducted

Netherlands, 

References & Publications (20)

Aglietti P, Baldini A, Vena LM, Abbate R, Fedi S, Falciani M. Effect of tourniquet use on activation of coagulation in total knee replacement. Clin Orthop Relat Res. 2000 Feb;(371):169-77. — View Citation

Alcelik I, Pollock RD, Sukeik M, Bettany-Saltikov J, Armstrong PM, Fismer P. A comparison of outcomes with and without a tourniquet in total knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials. J Arthroplasty. 2012 Mar;27(3):331-40. doi: 10.1016/j.arth.2011.04.046. Epub 2011 Sep 22. Review. — View Citation

American Academy of Orthopaedic Surgeons. Knee Arthroscopy. 2013. http://orthoinfo.aaos.org/topic.cfm?topic=a00299. Accessed April 15, 2014

Bovill EG, van der Vliet A. Venous valvular stasis-associated hypoxia and thrombosis: what is the link? Annu Rev Physiol. 2011;73:527-45. doi: 10.1146/annurev-physiol-012110-142305. Review. — View Citation

Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P, Ntita K, Salmistraro G, Frangos C, Rossi F, Cordova R, Franz F, Zucchetta P, Kontothanassis D, Andreozzi GM; KANT (Knee Arthroscopy Nadroparin Thromboprophylaxis) Study Group. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med. 2008 Jul 15;149(2):73-82. — View Citation

Estebe JP, Davies JM, Richebe P. The pneumatic tourniquet: mechanical, ischaemia-reperfusion and systemic effects. Eur J Anaesthesiol. 2011 Jun;28(6):404-11. doi: 10.1097/EJA.0b013e328346d5a9. Review. — View Citation

Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):381S-453S. doi: 10.1378/chest.08-0656. — View Citation

Hoogeslag RA, Brouwer RW, van Raay JJ. The value of tourniquet use for visibility during arthroscopy of the knee: a double-blind, randomized controlled trial. Arthroscopy. 2010 Sep;26(9 Suppl):S67-72. doi: 10.1016/j.arthro.2009.12.008. Epub 2010 May 13. — View Citation

Hoppener MR, Ettema HB, Henny CP, Verheyen CC, Büller HB. Symptomatic deep vein thrombosis and immobilization after day-care arthroscopy of the knee. J Thromb Haemost. 2005 Jan;3(1):185-7. — View Citation

Hoppener MR, Ettema HB, Henny CP, Verheyen CC, Büller HR. Low incidence of deep vein thrombosis after knee arthroscopy without thromboprophylaxis: a prospective cohort study of 335 patients. Acta Orthop. 2006 Oct;77(5):767-71. — View Citation

Hoppener MR, Ettema HB, Kraaijenhagen RA, Verheyen CC, Henny PC. Day-care or short-stay surgery and venous thromboembolism. J Thromb Haemost. 2003 Apr;1(4):863-5. — View Citation

Ilahi OA, Reddy J, Ahmad I. Deep venous thrombosis after knee arthroscopy: a meta-analysis. Arthroscopy. 2005 Jun;21(6):727-30. — View Citation

Johnson DS, Stewart H, Hirst P, Harper NJ. Is tourniquet use necessary for knee arthroscopy? Arthroscopy. 2000 Sep;16(6):648-51. — View Citation

Kageyama K, Nakajima Y, Shibasaki M, Hashimoto S, Mizobe T. Increased platelet, leukocyte, and endothelial cell activity are associated with increased coagulability in patients after total knee arthroplasty. J Thromb Haemost. 2007 Apr;5(4):738-45. — View Citation

Kam PC, Kavanagh R, Yoong FF. The arterial tourniquet: pathophysiological consequences and anaesthetic implications. Anaesthesia. 2001 Jun;56(6):534-45. Review. Erratum in: Anaesthesia 2001 Aug;56(8):821. Kavanaugh R [corrected to Kavanagh R]. — View Citation

Katsumata S, Nagashima M, Kato K, Tachihara A, Wauke K, Saito S, Jin E, Kawanami O, Ogawa R, Yoshino S. Changes in coagulation-fibrinolysis marker and neutrophil elastase following the use of tourniquet during total knee arthroplasty and the influence of neutrophil elastase on thromboembolism. Acta Anaesthesiol Scand. 2005 Apr;49(4):510-6. — View Citation

Ramos J, Perrotta C, Badariotti G, Berenstein G. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD005259. doi: 10.1002/14651858.CD005259.pub3. Review. — View Citation

Reikerås O, Clementsen T. Time course of thrombosis and fibrinolysis in total knee arthroplasty with tourniquet application. Local versus systemic activations. J Thromb Thrombolysis. 2009 Nov;28(4):425-8. doi: 10.1007/s11239-008-0299-6. Epub 2008 Dec 6. — View Citation

Schreijer AJ, Cannegieter SC, Meijers JC, Middeldorp S, Büller HR, Rosendaal FR. Activation of coagulation system during air travel: a crossover study. Lancet. 2006 Mar 11;367(9513):832-8. — View Citation

Sharrock NE, Go G, Sculco TP, Ranawat CS, Maynard MJ, Harpel PC. Changes in circulatory indices of thrombosis and fibrinolysis during total knee arthroplasty performed under tourniquet. J Arthroplasty. 1995 Aug;10(4):523-8. — View Citation

* Note: There are 20 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Change in parameters that reflect a hypoxic state assessed by pH Change in pH between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Change in parameters that reflect a hypoxic state assessed by pO2 Change in pO2 between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Change in parameters that reflect a hypoxic state assessed by pCO2 Change in pCO2 between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Change in parameters that reflect a hypoxic state assessed by Lactate Change in Lactate between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Change in parameters that reflect an inflammatory reaction assessed by WBCC Change in White Blood Cell Count (WBCC) between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Change in parameters that reflect an inflammatory reaction and/or endothelium involvement assessed by E-selectin Change in E-selectin between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Change in parameters that reflect an inflammatory reaction assessed by NETs Change in Neutrophil Extracellular traps (NETs) between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Outcome parameters that reflect involvement of the endothelium assessed by vWF Change in Von Willebrand Factor (vWF) between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Outcome parameters that reflect involvement of the endothelium assessed by thrombomodulin. Change in Thrombomodulin between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Outcome parameters that reflect involvement of the endothelium assessed by f 1+2 Change in Prothrombin fragments 1+2 (f 1+2) between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Outcome parameters that reflect a procoagulant state and thrombin formation assessed by D-dimer Change in D-dimer between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Outcome parameters that reflect a procoagulant state and thrombin formation assessed by PAI 1 Change in Plasmin Activator Inhibitor 1 (PAI 1) between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Outcome parameters that reflect a procoagulant state and thrombin formation assessed by tPA Change in Tissue plasminogen activator (tPA) between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Outcome parameters that reflect a procoagulant state and thrombin formation assessed by factor VIII Change in Factor VIII between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Outcome parameters that reflect a procoagulant state and thrombin formation assessed by TAT Change in Thrombin and Antithrombin complexes (TAT) between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Primary Outcome parameters that reflect a procoagulant state and thrombin formation assessed by PAP Change in Plasmin and antiplasmin complexes (PAP) between timepoints Change in parameters between timepoints; Before surgery (blood drawn approximately 1 hour before surgery), directly after surgery (blood drawn within 5 minutes), 1 hour after surgery.
Secondary Duration of surgery The total duration of surgery in minutes intraoperative, duration in minutes between first incision until closure
Secondary Duration of tourniquet use The total duration of tourniquet inflation in minutes intraoperative, duration in minutes between tourniquet inflation and deflation
Secondary Per-operative visibility Visibility during surgery, measured on a Visual Analogue Scale scale (0-10) Per-operative
See also
  Status Clinical Trial Phase
Completed NCT02247414 - Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Phase 4
Recruiting NCT02650453 - Ongoing Registry of Deep Venous Reconstructions N/A
Completed NCT02065388 - Pharmacogenetic Dosing of Warfarin Phase 3
Completed NCT00839657 - Clarification of Optimal Anticoagulation Through Genetics Phase 3
Terminated NCT00872079 - Personalized Warfarin Dosing by Genomics and Computational Intelligence N/A
Terminated NCT00521885 - Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients N/A
Completed NCT02892565 - Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System) N/A
Completed NCT00346424 - Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters Phase 3
Active, not recruiting NCT04349189 - Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
Recruiting NCT02238444 - Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Phase 4
Recruiting NCT02597218 - Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.
Completed NCT00986154 - Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Phase 3
Completed NCT00246025 - A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery. Phase 2
Completed NCT00097357 - BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery Phase 2/Phase 3
Completed NCT04645550 - Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT) Phase 4
Recruiting NCT02264743 - Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy Phase 4
Completed NCT01482273 - Ultrasound-enhanced Thrombolysis Versus Standard Catheter Directed Thrombolysis for Ilio-femoral Deep Vein Thrombosis N/A
Recruiting NCT01252420 - Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis Phase 4
Completed NCT01145859 - Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects Phase 1
Completed NCT00790335 - Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Phase 3